🏛️ Verified NIH Record • Updated 2026-04-22
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors (NCT04913285)
A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Pierre Fabre Medicament
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
Who can join: Review the eligibility criteria below.
Location: The Angeles Clinic — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (50 Sites)
Showing the first 25 of 50 sites.
- The Angeles Clinic — Los Angeles, California
- UCLA — Los Angeles, California
- University of California San Diego, Moores Cancer Center — San Diego, California
- University of California San Francisco — San Francisco, California
- Stanford Cancer Center — Stanford, California
- Sarah Cannon Research Institute Denver — Denver, Colorado
- Mayo Clinic - Florida — Jacksonville, Florida
- Sarah Cannon Research Institute - Florida Cancer Specialists — Orlando, Florida
- Mayo Clinic - Rochester — Rochester, Minnesota
- Atlantic Health — Morristown, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- NYU Langone — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Cleveland Clinic — Cleveland, Ohio
- Sarah Cannon Research Institute-Tennessee Oncology — Nashville, Tennessee
- MD Anderson — Houston, Texas
- Virginia Cancer Specialists — Fairfax, Virginia
- Calvary Mater Hospital Newcastle — Waratah, New South Wales
- Melanoma Institute Australia — Wollstonecraft, New South Wales
- Tasman Health Care — Southport, Queensland
- Austin Health — Heidelberg, Victoria
- Linear Clinical Research — Perth, Western Australia
- Harbin Medical University Cancer Hospital — Haerbin, Heilongjiang
- Linyi Cancer Hospital — Linyi, Shandong
- Beijing University Cancer Hospital — Beijing,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor, Adult
- A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody — Sarasota, Florida
- First-in-Human Study of ICT01 in Patients With Advanced Cancer — Gilbert, Arizona
- A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors — Los Angeles, California
- Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab — Los Angeles, California
- A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial — Scottsdale, Arizona
- A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression — Gilbert, Arizona
Explore by condition: All Solid Tumor, Adult clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.